The two gates every assessment must pass

For most patients researching this pathway, the first practical question is straightforward: does my situation actually qualify? Two structural criteria must both be satisfied before any defect-specific assessment begins — and the order in which they sit on the treatment ladder matters as much as the criteria themselves.

The first gate is documented failure of conservative management. This means a meaningful trial of physiotherapy, load modification, and activity adjustment — and, where clinically appropriate, injection therapies such as corticosteroid or hyaluronic acid. The rationale is deliberate: a structural-level intervention is only warranted once simpler measures have demonstrably not held. Patients who have not yet worked through conservative care are not at the right point on the pathway for this treatment.

The second gate is MRI-confirmed cartilage damage. Self-reported symptoms and clinical examination alone are not sufficient to qualify. Imaging maps defect location, depth, the integrity of the surrounding cartilage, and any subchondral changes that could redirect management — details no physical assessment can reliably provide. Pain severity, however significant, is explicitly not the qualifying threshold; structural evidence of cartilage loss is.

Together, these two gates define where this treatment deliberately sits: in the clinical space between 'conservative care has stalled' and 'end-stage joint disease requiring replacement'. It is not a first-line option, nor is it reserved for patients who have exhausted all surgical possibilities. Understanding that positioning helps explain why both criteria are non-negotiable — and why a clinic proceeding without pre-treatment MRI review is, by any reasonable standard, a red flag.

What counts as a meaningful conservative care trial

The critical word in the first gate is documented — and understanding what that means separates patients who incorrectly self-disqualify from those who are genuinely ready for the next step.

Adequacy is judged on evidence of failed effect, not on time elapsed. No fixed minimum duration is specified in the clinical framework; the relevant question is whether a genuine trial — of physiotherapy, activity modification, and where appropriate symptomatic injection therapies — has been attempted and has demonstrably not resolved the problem. A course of physiotherapy that produced no meaningful functional improvement counts. A sustained period of load reduction that left symptoms unchanged counts. What does not count is a single appointment, a self-directed few weeks of stretching, or one corticosteroid injection taken as the only conservative step before requesting a structural intervention.

The word "meaningful" in the clinical language is deliberate. It implies the modality was actually applied, compliance was reasonable, and the outcome — or absence of it — is on record. That last point matters more than it might initially seem: documented failure means a clinician can trace what was tried, over what period, and with what result. Patients who have worked through multiple approaches without significant relief are typically well placed at this point in the assessment process.

The rationale behind this gate is clinical rather than procedural: a structural-level intervention is only warranted once simpler, lower-risk measures have demonstrably not held.

How defect size and grade shape the decision

Cartilage damage does not qualify or disqualify in isolation — the pattern, depth, and extent of the defect collectively determine which clinical pathway applies and whether the collagen scaffold is an appropriate fit.

Focal defects: grade and size thresholds

The focal defect pathway targets damage graded Outerbridge (ICRS) Grade III or Grade IV. In plain terms, Grade III means at least half the cartilage thickness has been lost but the underlying bone surface remains intact; Grade IV means the damage has reached or penetrated the subchondral bone. Both grades describe structural loss significant enough that the joint surface can no longer reliably self-repair.

Size matters alongside grade. The standard focal indication covers lesions of up to approximately 3 cm² — roughly the footprint of a large thumbnail. The CE-mark for ChondroFiller® extends that ceiling to 6 cm², which is already broader than the typical range suited to microfracture, a technique generally considered appropriate for defects under 2–4 cm². Published comparative data show microfracture reoperation rates of up to 41%, largely because the fibrocartilage it produces is mechanically inferior to hyaline-like tissue; the collagen scaffold sits within a 3–8% reoperation range across defects up to 6 cm². Patients with moderate-to-large focal lesions who fall outside the microfracture indication may therefore still fall comfortably within the scaffold's size envelope.

Diffuse wear and osteoarthritis

Not all cartilage damage is focal. For patients with more widespread joint wear — including those with Kellgren-Lawrence Grade I to III osteoarthritis, or who have been told clinically that their joint is 'bone on bone' — the injection pathway operates without a fixed defect-size ceiling. As an injectable scaffold, the material can be placed to coat the entire articular surface in a single outpatient appointment, rather than targeting a bounded lesion alone. Even patients who might appear to have exhausted cartilage options are not automatically excluded from assessment.

This routing decision — focal versus diffuse, and which pathway to follow — depends on the MRI findings already described: defect grade, location, surrounding cartilage borders, and subchondral status are what make precise triage possible.

Age, lifestyle, and conditions that are typically eligible

One of the most common reasons patients self-exclude from assessment is the assumption that this treatment is reserved for younger, high-level athletes with a sports injury. The evidence does not support that assumption.

Age

No published strict upper age limit exists for the injection pathway. Active adults in their 60s, 70s, and beyond who want to defer or avoid joint replacement are considered a core assessment group — not an exception to it. What matters clinically is whether the joint meets the structural and biological criteria for treatment, not the patient's age at the time of referral.

Body weight

No restrictive BMI threshold is stated for the injectable collagen scaffold pathway. BMI may remain relevant to the broader clinical picture — joint loading, rehabilitation tolerance, and the risk profile of any later surgical step if required — but it is not a disqualifying threshold for assessment itself.

Eligible conditions

The range of aetiologies the evidence covers is wider than many patients assume:

• Post-traumatic chondral lesions, including damage from past acute injuries or fractures
• Osteochondritis dissecans (OCD)
• Sport-related cartilage injury
• Damage arising after meniscal or ligament reconstruction
• Early-to-moderate degenerative osteoarthritis and progressive age-related cartilage wear

What these presentations share is cartilage loss meeting the grade and pattern criteria already described — not a particular age bracket, activity level, or route to injury.

Joint problems that must be treated before the injection

Structural issues elsewhere in the joint do not automatically rule a patient out — but they do affect the order in which treatment happens.

The collagen scaffold works by occupying and stabilising a cartilage defect in a mechanically sound environment. If the forces acting on the repair site are already abnormal, the scaffold is working against physics rather than with it. Three structural factors are assessed as part of any candidacy review:

• Alignment deformity. Significant varus or valgus malalignment concentrates load unevenly across the joint surface. Where malalignment is driving or accelerating the cartilage loss, it needs to be corrected — otherwise the repair site bears disproportionate stress from the outset.
• Ligament instability. An unrepaired ACL rupture or comparable instability creates shear forces the scaffold is not designed to resist. The injectable collagen addresses cartilage loss; it does not replace ligament function.
• Meniscal deficits. Where a meniscal problem is actively contributing to the wear pattern, that component of the joint picture is assessed and managed as part of the same clinical episode.

Importantly, these are sequencing considerations rather than permanent exclusions. Many patients have a coexisting mechanical issue addressed alongside the cartilage treatment as part of a coordinated plan, rather than in a separate prior procedure. The assessment stage is designed precisely to map this picture and establish the right order of steps.

The four clinical pathways and what the evidence reports

The structured candidacy review does not simply return a yes or no. Assessment across four dimensions — joint mechanics and stability, the biological environment inside the joint, the condition of the remaining tissue, and how far wear has progressed — routes each patient to one of four clinical pathways.

Prevention targets early focal damage where the primary aim is halting further cartilage loss before a Grade III or IV lesion becomes established. Regeneration is the active-repair pathway for confirmed focal Grade III or IV defects within a mechanically sound joint — the setting where the injectable collagen scaffold has the most direct structural role. Combination applies where cartilage treatment runs in parallel with another clinical step, such as addressing ligament instability, a meniscal deficit, or alignment, as part of the same coordinated plan. Support covers diffuse or advanced joint wear — including patients described clinically as bone on bone — where the scaffold is applied to cushion and protect the broader articular surface rather than fill a single contained lesion.

Published series on knee patients report IKDC functional scores improving by approximately 30 points over 12 months. These outcome figures reflect the treated population across defect types rather than any single pathway in isolation. On reoperation, published data report rates of approximately 3–8% across defect sizes up to 6 cm² — compared with published figures of up to 41% for microfracture and up to 37% for the two-stage MACI procedure. The scaffold is described in published sources as producing hyaline-like repair tissue delivered in a single outpatient appointment, in contrast to MACI's two-stage approach.

Conditions such as active joint infection or inflammatory arthropathy flare are implied exclusions in the clinical literature, though formally published contraindication lists from independent guidelines are not yet established — a clinician assessing individual suitability will address this directly at consultation.